HURA NASDAQ
TuHURA Biosciences, Inc.
1W: -3.6%
1M: -1.4%
3M: -4.0%
YTD: +184.2%
1Y: -25.3%
3Y: -52.4%
5Y: -97.4%
$2.13
-0.08 (-3.62%)
Pre-Market: $2.41 (+0.28, +12.91%)
Weekly Expected Move ±10.6%
$2
$2
$2
$2
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$135.6M
52W Range0.41-3.9
Volume213,022
Avg Volume586,259
Beta-0.04
Dividend—
Analyst Ratings
Company Info
CEOJames A. Bianco
Employees22
SectorHealthcare
IndustryBiotechnology
IPO Date2013-02-22
Websitetuhurabio.com
10500 University Center Drive
Tampa, FL 33612
US
Tampa, FL 33612
US
+1 813 514 8373
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Latest News
Analysts Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $9.00
HURA: Refining TBS-2025 Development Plan
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences secures $50 million credit facility, extends cash runway to 2028
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bianco James A. | G-Gift | 150,000 | — | 2026-05-28 |
| Tendler Craig | A-Award | 156,240 | $1.29 | 2026-02-12 |
| Ng George K | A-Award | 156,240 | $1.29 | 2026-02-12 |
| MANUSO JAMES S J | A-Award | 156,240 | $1.29 | 2026-02-12 |
| List Alan | A-Award | 156,240 | $1.29 | 2026-02-12 |